Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients
暂无分享,去创建一个
T. Pawlik | T. Zimmers | M. Bloomston | M. Dillhoff | G. Lesinski | D. Guttridge | P. Hart | E. Talbert | C. Schmidt | J. Chakedis | M. Ramsey | M. Farren | H. Lewis | P. Rajasekera | E. Haverick | Angela Sarna | A. Sarna | Mary E. Dillhoff
[1] T. Pawlik,et al. Predictors of Pancreatic Cancer–Associated Weight Loss and Nutritional Interventions , 2017, Pancreas.
[2] A. Fiorillo,et al. Effects of acute physical exercise on oxidative stress and inflammatory status in young, sedentary obese subjects , 2017, PloS one.
[3] B. Adams-Huet,et al. The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome. , 2017, Journal of diabetes and its complications.
[4] G. Marko‐Varga,et al. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma , 2017, The British journal of surgery.
[5] M. Muscaritoli,et al. Perspectives of health care professionals on cancer cachexia: results from three global surveys , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] S. Anker,et al. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016 , 2016, Journal of cachexia, sarcopenia and muscle.
[7] Richard Nicoletti,et al. Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss. , 2016, Oncology letters.
[8] T. Welling,et al. GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. , 2016, Cancer discovery.
[9] R. Parish,et al. Resting Heart Rate Variability, Inflammation, and Insulin Resistance in Overweight and Obese Adolescents. , 2016, Metabolic syndrome and related disorders.
[10] J. Davis,et al. Role of MCP-1 on Inflammatory Processes and Metabolic Dysfunction Following High-Fat Feedings in the FVB/N Strain , 2015, International Journal of Obesity.
[11] A. Vigano,et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia , 2015, Journal of cachexia, sarcopenia and muscle.
[12] J. Otoch,et al. Cachexia‐associated adipose tissue morphological rearrangement in gastrointestinal cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.
[13] G. Lesinski,et al. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer , 2015, Clinical Cancer Research.
[14] G. Trinchieri,et al. Systemic Inflammation in Cachexia – Is Tumor Cytokine Expression Profile the Culprit? , 2015, Front. Immunol..
[15] S. Anker,et al. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015 , 2015, Journal of cachexia, sarcopenia and muscle.
[16] Shiying Yu,et al. An Epidemiological Survey of Cachexia in Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status , 2015, Nutrition and cancer.
[17] Shi Qian,et al. How to analyze tumor stage data in clinical research. , 2015, Journal of thoracic disease.
[18] Richard Nicoletti,et al. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.
[19] T. Mukohara,et al. Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer , 2014, PloS one.
[20] N. Wentzensen,et al. Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[21] C. Jenkinson,et al. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus , 2014, Acta Diabetologica.
[22] R. Browne,et al. Performance of Multiplex Cytokine Assays in Serum and Saliva among Community-Dwelling Postmenopausal Women , 2013, PloS one.
[23] Thomas Pausch,et al. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. , 2012, Surgery.
[24] D. Bar-Sagi,et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.
[25] N. Jhala,et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.
[26] Sunita Ghosh,et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma , 2012, British Journal of Cancer.
[27] A. Sümer,et al. The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic , 2012, Human & experimental toxicology.
[28] Dale P Sandler,et al. Accuracy and reliability of self-reported weight and height in the Sister Study , 2011, Public Health Nutrition.
[29] M. Ashraf,et al. Artemisinins and immune system. , 2011, European journal of pharmacology.
[30] T. Hyslop,et al. Serum Monocyte Chemoattractant Protein-1 in Pancreatic Cancer , 2011, Journal of oncology.
[31] F. López‐Soriano,et al. Anti-inflammatory therapies in cancer cachexia. , 2011, European journal of pharmacology.
[32] J. Margolick,et al. Multisite Comparison of High-Sensitivity Multiplex Cytokine Assays , 2011, Clinical and Vaccine Immunology.
[33] Paula Ravasco,et al. Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.
[34] P. Iversen,et al. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer , 2011, Archives of physiology and biochemistry.
[35] M. Krzystek-Korpacka,et al. Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. , 2010, Cytokine.
[36] L. Kuller,et al. Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in Japanese, white, and Japanese American middle-aged men. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[37] G. Taffet,et al. Adipokines in Patients With Cancer Anorexia and Cachexia , 2010, Journal of Investigative Medicine.
[38] M. Tisdale. Mechanisms of cancer cachexia. , 2009, Physiological reviews.
[39] G. Wakabayashi,et al. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs , 2009, International Journal of Clinical Oncology.
[40] H. Friess,et al. Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function , 2009, BMC Cancer.
[41] G. Frühbeck,et al. Circulating Markers of Inflammation and Their Link to Indices of Adiposity , 2008, Obesity Facts.
[42] Tony Reiman,et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[43] H. Friess,et al. Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.
[44] T. McDonald,et al. Monocyte Chemoattractant Protein-1 Deficiency Fails to Restrain Macrophage Infiltration Into Adipose Tissue , 2008, Diabetes.
[45] G. Frühbeck,et al. Proinflammatory Cytokines in Obesity: Impact of Type 2 Diabetes Mellitus and Gastric Bypass , 2007, Obesity surgery.
[46] Graham M Lord,et al. Absence of CC Chemokine Ligand 2 Does Not Limit Obesity-Associated Infiltration of Macrophages Into Adipose Tissue , 2007, Diabetes.
[47] C. Ko,et al. Validation of the 6th edition AJCC pancreatic cancer staging system , 2007, Cancer.
[48] J. Fernández-Real,et al. Monocyte Chemoattractant Protein‐1 in Obesity and Type 2 Diabetes. Insulin Sensitivity Study , 2007, Obesity.
[49] T. Kadowaki,et al. Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance* , 2006, Journal of Biological Chemistry.
[50] R. Kitazawa,et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.
[51] R. Yu,et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters , 2006, International Journal of Obesity.
[52] R. Skipworth,et al. Cancer cachexia and fatigue. , 2006, Clinical medicine.
[53] H. Kotani,et al. Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice* , 2003, Journal of Biological Chemistry.
[54] P. Allavena,et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. , 2003, Cancer research.
[55] E. Villanueva. The validity of self-reported weight in US adults: a population based cross-sectional study , 2001, BMC public health.
[56] G A Colditz,et al. Physical activity, obesity, height, and the risk of pancreatic cancer. , 2001, JAMA.
[57] M. Breslow,et al. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. , 2001, The Journal of clinical endocrinology and metabolism.
[58] M. Goldberg,et al. Validity of self-reported weight and height in the French GAZEL cohort , 2000, International Journal of Obesity.
[59] B. Rollins,et al. Monocyte chemoattractant protein-1. , 1999, Chemical immunology.
[60] Joseph R. Bertino,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.
[61] C. Begg,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.